BioTime has formed a new science and technology committee to oversee the development and commercialization of its regenerative medicine and oncology tech.
Newly appointed director and former US FDA commissioner Andrew von Eschenbach joins the three-member committee alongside Optimer Pharmaceuticals CEO Pedro Lichtinger, and Neal Bradsher who is president of Broadwood Capital.
“The committee looks forward to working with the management of BioTime and its subsidiaries in advancing breakthrough products into clinical trials, including those anticipated to begin this year for the use of HyStem-Rx as an implantable matrix for cell delivery in cosmetic and reconstructive surgeries,” said von Eschenbach.
Alfred Kingsley, BioTime chairman, added: “This is an exciting time for the emerging field of regenerative medicine.”
New appointments at biopharma and equipment companies also feature in this week's column.
Plus other people on the move in the pharma industry in this week's column.
People are on the move at Baxter, Merck & Co., Johnson & Johnson, and elsewhere in this...
Twin changes at AstraZeneca's MedImmune kick off this week's gallery, as well as jobs news from Europe
UCB has more than drugs in its 2015 pipeline, while BUPA and biotechs hire new recruits.